Alemtuzumab-Induced Thyroid Dysfunction Exhibits Distinctive Clinical and Immunological Features | Zendy

Nadia Pariani | Zendy; Mark Willis | Zendy; Ilaria Muller | Zendy; Sarah Healy | Zendy; Taha Nasser | Zendy; Anne McGowan | Zendy; Greta Lyons | Zendy; Joanne L. Jones | Zendy; Krishna Chatterjee | Zendy; Colin Dayan | Zendy; Neil P. Robertson | Zendy; Alasdair Coles | Zendy; Carla Moran | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Alemtuzumab-Induced Thyroid Dysfunction Exhibits Distinctive Clinical and Immunological Features

Author(s) -

Nadia Pariani,

Mark Willis,

Ilaria Muller,

Sarah Healy,

Taha Nasser,

Anne McGowan,

Greta Lyons,

Joanne L. Jones,

Krishna Chatterjee,

Colin Dayan,

Neil P. Robertson,

Alasdair Coles,

Carla Moran

Publication year - 2018

Publication title -

the journal of clinical endocrinology and metabolism

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.206

H-Index - 353

eISSN - 1945-7197

pISSN - 0021-972X

DOI - 10.1210/jc.2018-00359

Subject(s) - medicine , alemtuzumab , trab , thyroidectomy , thyroid peroxidase , thyroiditis , multiple sclerosis , gastroenterology , etiology , thyroid , autoimmune thyroiditis , endocrinology , graves' disease , immunology , transplantation

Alemtuzumab, a highly effective treatment for multiple sclerosis (MS), predisposes to Graves disease (GD), with a reportedly indolent course.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom

About

About Careers Publisher Partners Contact Us Get Organisational Trial or Quote

Learn

FAQs Blog Terms of Use Privacy Policy

Download the Zendy App

Address

About

Learn

Download the Zendy App

Discover

Explore